Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: A case-control study

Ikram Sghaier; Sabrina Zidi; Rabeb M El-Ghali; Amira Daldoul; Gulzhanat Aimagambetova; Wassim Y Almawi

doi:10.1016/j.gene.2022.146969

Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: A case-control study

Gene. 2023 Jan 30:851:146969. doi: 10.1016/j.gene.2022.146969. Epub 2022 Oct 17.

Authors

Ikram Sghaier¹, Sabrina Zidi¹, Rabeb M El-Ghali², Amira Daldoul³, Gulzhanat Aimagambetova⁴, Wassim Y Almawi⁵

Affiliations

¹ Faculty of Sciences, El-Manar University, Tunis, Tunisia.
² Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
³ Department of Medical Oncology, Fattouma Bourguiba University Hospital, Monastir, Tunisia.
⁴ Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan.
⁵ Faculty of Sciences, El-Manar University, Tunis, Tunisia; Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan. Electronic address: wyoussefalmaoui@brocku.ca.

PMID: 36261089
DOI: 10.1016/j.gene.2022.146969

Abstract

Background: We previously reported on the association between ESR1 and ESR2 gene variants and heightened risk of breast cancer (BC). Here we investigated the association of common ESR1 and ESR2 gene variants with triple negative BC (TNBC).

Methods: This retrospective case-control study involved 488 BC patients (130 TNBC, 358 non-TNBC patients). ESR1 (rs2234693, rs9340799, rs3020314, rs3798577) and ESR2 (rs928554, rs944459, rs4986938, rs1256049, rs1256030, rs1271572) genotyping was done by real-time PCR.

Results: While minor allele frequencies (MAF) of ESR1 variants were comparable between TNBC and non-TNBC subjects, significantly higher ESR2 rs1256049 MAF was seen in TNBC patients. Significantly higher frequency of ESR1 rs3798577 T/C and C/C genotypes were noted in TNBC cases, and significant differences were seen in ESR2 rs928554, rs1256049, and rs1271572 genotype distribution. Increased TNBC risk was associated with ESR1 rs3798577 T/C and C/C genotypes according to codominant and dominant models, while positive association of ESR2 rs928554 with TNBC was seen according to codominant and recessive models, and positive association of ESR2 rs1256049 with TNBC was seen according to codominant and dominant models. Positive interactions were noted between ESR2 rs1271572-ESR1 rs3020314, ESR2 rs1271572-ESR1 rs9340799, and ESR2 rs1271572-ESR1 rs2234693, ESR2 rs4986938-ESR1 rs2234693, and ESR2 rs928554-ESR1 rs9340799. Haplotype analysis confirmed the positive association of ESR1 CATT with TNBC, while ACGGCTC and ACGGTT ESR2 haplotypes were positively associated with TNBC.

Conclusion: Results of this study confirmed the association of unique ESR1 and ESR2 genetic variants with altered risk of TNBC. This suggests possible diagnostic and prognostic role of these variants with TNBC independent of their association with BC.

Keywords: Breast cancer; Estrogen receptor; Genotypes; Haplotypes; Triple negative breast cancer.

MeSH terms

Case-Control Studies
Estrogen Receptor alpha* / genetics
Estrogen Receptor beta* / genetics
Female
Genetic Predisposition to Disease
Genotype
Humans
Polymorphism, Single Nucleotide
Retrospective Studies
Triple Negative Breast Neoplasms* / genetics

Substances

ESR2 protein, human
Estrogen Receptor alpha
Estrogen Receptor beta
ESR1 protein, human